ViewRay, Inc. (VRAY) Trims Q2 Loss

Go back to ViewRay, Inc. (VRAY) Trims Q2 Loss

ViewRay Reports Second Quarter 2016 Financial Results

August 15, 2016 4:01 PM EDT

CLEVELAND, Aug. 15, 2016 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) today announced financial results for the second quarter and six months ended June 30, 2016.

"We are making exciting progress, highlighted by the continued development of our MRIdian linac technology.  During site visits to assess the technology, clinicians and scientists have commented that they are particularly impressed by the sharpness of the beam and the high dose rate," said Chris A. Raanes, President and Chief Executive Officer of ViewRay. "Recently, we presented the first technical data on the capabilities of MRIdian linac technology... More

ViewRay's MRIdian System Receives Japanese Regulatory Approval (Shonin)

August 15, 2016 8:35 AM EDT

CLEVELAND, Aug. 15, 2016 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today that the company received Shonin approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) to market the MRIdian System.  

MRIdian is the world's first and only clinical MRI-guided radiation therapy system. The MRIdian system is a unique medical instrument that integrates full-time MR imaging, cobalt radiation delivery, and intelligent software automation. Using the MRIdian system, clinicians can see soft tissue, and visualize and adjust the dose all in real time, on live anatomy. With MRIdian this is done... More